Biotech CTO Executive Search.
Retained, partner-led search for the technical leader who turns a molecule into a product: Chief Technology Officers and the technical operations leadership around them, calibrated to stage, modality, and the mandate the company is actually hiring against.
The CTO owns the largest controllable risk.
Source: Phase 3 Search analysis of the FDA’s full published CRL archive, July 2026, including the reconciliation of the widely quoted 74% (The Complete Response Letter Report; methodology). Jefferies’ read of the same archive (more than half cite manufacturing, 41% product quality, May 2026) points the same way. Read the full argument.
A biotech hires its CTO to keep five promises: that the molecule is Possible, that the process is Reproducible, that the record is Acquirable, that the platform is Scalable, and that supply is Durable. That is not a lab function; it is the operating instrument between the science and the capital plan. We wrote the governance model for the seat, the CTO Mandate Framework, and we search against it.
The technical leadership spine.
The seat changes with the stage.
The same title hides three different jobs. We calibrate which one you are hiring before we open the market.
The first technical leader
Often fractional or VP-level: the person who makes the molecule Possible, sets the analytical spine, and keeps early process decisions from becoming later rework. We advise when the full CTO seat is premature, and what to hire instead.
The first true CTO
Scale-up, comparability, and the shift from “it worked once” to “it works every time.” The founding technical profile often needs to evolve here; we read whether the mandate has moved before the search opens.
The commercial-readiness CTO
Inspection-ready operations, dual-sourced supply, and a technical record an acquirer’s diligence team can follow without an interpreter. The seat that decides whether approval converts to launch.
We assess every CTO against five mandates.
The CTO Mandate Framework, published May 2026 and downloaded 250+ times in its first month, defines the five promises a technical leader must be able to keep. It is the diagnostic we run before any longlist exists, and the language we give boards for the seat.
Diagnostic first, then the market.
Every CTO search begins with the mandate read: which of the five mandates the next two years actually demand, what the current organisation can already hold, and where the gap is structural rather than personal. Then a partner runs the market end to end, through the CMC, Technical Operations, and Quality networks we have worked for 13 years, not a résumé database. The adjacent seats have their own practices: Quality and QA executive search and CDMO executive search, inside the wider practice.
Biotech CTO executive search, in plain terms.
What does a biotech CTO own?
The technical enterprise: CMC, process and analytical development, manufacturing (internal or through CDMO partners), supply chain, and the technical interface with Quality and Regulatory. In the language of the CTO Mandate Framework, the CTO makes the molecule Possible, Reproducible, Acquirable, Scalable, and Durable.
When should a biotech hire its first CTO?
Most companies need the seat as they approach IND and first-in-human, when process decisions start to lock in cost and comparability. Complex modalities such as cell and gene therapy need it earlier. Before that point, a fractional or VP-level technical leader is often the right instrument, and we advise on which.
What is the difference between a CTO and a CSO in biotech?
The CSO owns the science: discovery, pipeline, and the question of what to make. The CTO owns turning that science into a manufacturable, approvable, supplyable product: CMC, technical operations, and quality interface. Early organisations often blur the two seats; the mandates are distinct.
How does Phase 3 run a biotech CTO search?
Diagnostic first. We read the company against the five mandates of the CTO Mandate Framework, agree with the board which mandates the next two years demand, and only then build the market map. A partner runs the search end to end across the CMC, Technical Operations, and Quality networks we have worked for 13 years.
The five mandates, in depth.
One article per mandate: what it demands, how it shows up in diligence and inspection, and the leader profile it calls for.
Run the diagnostic on your next hire.
Thirty minutes. A structured read on the role. We tell you whether search is the right product, whether the brief reflects the company you are actually inheriting, and whether the leadership architecture sits where it needs to be for your next capital event.